Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease:clinical outcomes in real-world patients from the DANBIO registry

Autor: Hafsah Nabi, Oliver Hendricks, Dorte Vendelbo Jensen, Anne Gitte Loft, Jens Kristian Pedersen, Søren Andreas Just, Kamilla Danebod, Heidi Lausten Munk, Salome Kristensen, Natalia Manilo, Ada Colic, Asta Linauskas, Pia Høger Thygesen, Louise Brot Christensen, Maren Høgberget Kalisz, Niels Lomborg, Stavros Chrysidis, Johnny Lillelund Raun, Marlene Andersen, Frank Mehnert, Niels Steen Krogh, Merete Lund Hetland, Bente Glintborg

Publikováno v: Nabi, H, Hendricks, O, Jensen, D V, Loft, A G, Pedersen, J K, Just, S A, Danebod, K, Munk, H L, Kristensen, S, Manilo, N, Colic, A, Linauskas, A, Thygesen, P H, Christensen, L B, Kalisz, M H, Lomborg, N, Chrysidis, S, Raun, J L, Andersen, M, Mehnert, F, Krogh, N S, Hetland, M L & Glintborg, B 2022, ' Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease : clinical outcomes in real-world patients from the DANBIO registry ', RMD Open, vol. 8, no. 2, e002560 . https://doi.org/10.1136/rmdopen-2022-002560
Nabi, H, Hetland, M L, Loft, A G, Hendricks, O, Jensen, D, Pedersen, J K, Just, S A, Danebod, K, Munk, H L, Kristensen, S, Manilo, N, Colic, A, Linauskas, A, Thygesen, P H, Christensen, L B, Kalisz, M H, Lomborg, N, Grydehøj, J, Raun, J, Ahmed, R, Mehnert, F, Krogh, N S & Glintborg, B 2022, ' INFLIXIMAB BIOSIMILAR-TO-BIOSIMILAR SWITCHING IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES: CLINICAL OUTCOMES IN REAL-WORLD PATIENTS FROM THE DANBIO REGISTRY ', Annals of the Rheumatic Diseases, vol. 81, no. Suppl. 1, OP0065, pp. 45-46 . https://doi.org/10.1136/annrheumdis-2022-eular.2306
Nabi, H, Hendricks, O, Jensen, D V, Loft, A G, Pedersen, J K, Just, S A, Danebod, K, Munk, H L, Kristensen, S, Manilo, N, Colic, A, Linauskas, A, Thygesen, P H, Christensen, L B, Kalisz, M H, Lomborg, N, Chrysidis, S, Raun, J L, Andersen, M, Mehnert, F, Krogh, N S, Hetland, M L & Glintborg, B 2022, ' Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease : Clinical outcomes in real-world patients from the DANBIO registry ', RMD Open, vol. 8, no. 2, 002560 . https://doi.org/10.1136/rmdopen-2022-002560
Nabi, H, Hendricks, O, Jensen, D V, Loft, A G, Pedersen, J K, Just, S A, Danebod, K, Munk, H L, Kristensen, S, Manilo, N, Colic, A, Linauskas, A, Thygesen, P H, Christensen, L B, Kalisz, M H, Lomborg, N, Chrysidis, S, Raun, J L, Andersen, M, Mehnert, F, Krogh, N S, Hetland, M L & Glintborg, B 2022, ' Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease : Clinical outcomes in real-world patients from the DANBIO registry ', RMD open, vol. 8, no. 2, 002560 . https://doi.org/10.1136/rmdopen-2022-002560

ObjectiveSuccessful uptake of biosimilars in rheumatology is limited by lack of real-world evidence regarding effectiveness of biosimilar-to-biosimilar switching. We investigated infliximab biosimilars CT-P13-to-GP1111 switching among patients with r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bcafac3b27cbee58119c12faba1e028
https://vbn.aau.dk/da/publications/1224b0b0-ee61-4f51-a117-2bb3d48fd527

Lower odds of remission among women with rheumatoid arthritis: A cohort study in the Swiss Clinical Quality Management cohort

Autor: Vallejo-Yagüe, Enriqueta, Pfund, Julia N, Burkard, Theresa, Clair, Carole, Micheroli, Raphael, Möller, Burkhard, Finckh, Axel, Burden, Andrea M

Publikováno v: PLoS ONE, 17 (10)
Vallejo-Yagüe, Enriqueta; Pfund, Julia N; Burkard, Theresa; Clair, Carole; Micheroli, Raphael; Möller, Burkhard; Finckh, Axel; Burden, Andrea M (2022). Lower odds of remission among women with rheumatoid arthritis: A cohort study in the Swiss Clinical Quality Management cohort. PLoS ONE, 17(10), e0275026. Public Library of Science 10.1371/journal.pone.0275026
PloS one, vol. 17, no. 10, pp. e0275026

Objective To compare the likelihood of achieving remission between men and women with rheumatoid arthritis (RA) after starting their first biologic or targeted synthetic disease-modifying anti-rheumatic drug (b/tsDMARD). Methods This cohort study in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a7cd600ce4010d64393f3ccbb8bf401
https://hdl.handle.net/20.500.11850/581840

Higher levels of anti-phosphorylcholine autoantibodies in early rheumatoid arthritis indicate lower risk of incident cardiovascular events

Autor: Ingiäld Hafström, Maria Andersson, Johan Frostegård, Sofia Ajeganova

Publikováno v: Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-11 (2021)
Arthritis Research & Therapy

Background The increased risk of cardiovascular events (CVE) in rheumatoid arthritis (RA) is not fully explained by traditional risk factors. Immuno-inflammatory mechanisms and autoantibodies could be involved in the pathogenesis of atherosclerotic d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::702c3f591d7f3994ee1478faf5dc6cc7
https://doaj.org/article/7dbc9cefd85f45fbbd8e1e0ec9c82672

Two-year cost-effectiveness of different COBRA-like intensive remission induction schemes in early rheumatoid arthritis: a piggyback study on the pragmatic randomised controlled CareRA trial

Autor: René Westhovens, Kristien Van der Elst, Johan Joly, Veerle Stouten, Annelies Boonen, S. Pazmino, Patrick Verschueren, Diederik De Cock

Publikováno v: Annals of the Rheumatic Diseases, 79(5), 556-565. BMJ Publishing Group

ObjectivesTo evaluate the cost-effectiveness of treat-to-target strategies among recently diagnosed patients with rheumatoid arthritis (RA) using methotrexate (MTX) and a step-down glucocorticoid (GC) scheme (COBRA Slim) compared with (1) this combin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48cd1900c9682219bdc8e423a3d2b43c
https://doi.org/10.1136/annrheumdis-2019-216874

The effect of a multidisciplinary lifestyle program for patients with rheumatoid arthritis, an increased risk for rheumatoid arthritis or with metabolic syndrome-associated osteoarthritis

Autor: Max Nieuwdorp, Henriët van Middendorp, Wendy Walrabenstein, Johanna M. van Dongen, Dirkjan van Schaardenburg, Carlijn A. Wagenaar, Catharina S. de Jonge, Laurette van Boheemen, Marike van der Leeden, Peter J.M. Weijs

Publikováno v: Trials, 22(1):715. BioMed Central
Trials, 22. Springer Science and Business Media LLC
Walrabenstein, W, van der Leeden, M, Weijs, P, van Middendorp, H, Wagenaar, C, van Dongen, J M, Nieuwdorp, M, de Jonge, C S, van Boheemen, L & van Schaardenburg, D 2021, ' The effect of a multidisciplinary lifestyle program for patients with rheumatoid arthritis, an increased risk for rheumatoid arthritis or with metabolic syndrome-associated osteoarthritis : the "Plants for Joints" randomized controlled trial protocol ', Trials, vol. 22, 715, pp. 1-11 . https://doi.org/10.1186/s13063-021-05682-y
Trials
Trials, 22:715, 1-11. BioMed Central
Walrabenstein, W, van der Leeden, M, Weijs, P, van Middendorp, H, Wagenaar, C, van Dongen, J M, Nieuwdorp, M, de Jonge, C S, van Boheemen, L & van Schaardenburg, D 2021, ' The effect of a multidisciplinary lifestyle program for patients with rheumatoid arthritis, an increased risk for rheumatoid arthritis or with metabolic syndrome-associated osteoarthritis : the "Plants for Joints" randomized controlled trial protocol ', Trials, vol. 22, no. 1, 715, pp. 715 . https://doi.org/10.1186/s13063-021-05682-y
Trials, Vol 22, Iss 1, Pp 1-11 (2021)

Low-grade inflammation and metabolic syndrome are seen in many chronic diseases, including rheumatoid arthritis (RA) and osteoarthritis (OA). Lifestyle interventions which combine different non-pharmacological therapies have shown synergizing effects

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb3989e7359a576b6d7a30bfc6288d1c
https://hdl.handle.net/1887/3254682